Found 12 articles for: "Androgenetic Alopecia"
Persistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series
March 2026 | Volume 25 | Issue 3 | Original Article | 951 | Copyright © March 2026
Background: Androgenetic alopecia (AGA) is the most common cause of hair loss. To minimize systemic adverse effects of 5-alpha-reductase inhibitors, dutasteride mesotherapy has g...
Read MoreUpdates on Therapeutic Approaches for Management of Androgenetic Alopecia: A Review
March 2026 | Volume 25 | Issue 3 | Original Article | 240 | Copyright © March 2026
Androgenetic alopecia (AGA) is a common, progressive form of nonscarring hair loss, affecting both men and women. Its pathogenesis is largely driven by androgenic factors, including elevated dihy...
Read MoreMicroneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia
October 2025 | Volume 24 | Issue 10 | Editorials | e59 | Copyright © October 2025
Hair Transplantation in Women
September 2025 | Volume 24 | Issue 9 | Original Article | 851 | Copyright © September 2025
Background: Hair transplantation is a widely used treatment for androgenetic alopecia (AGA) and other hair loss conditions, with increasing demand from women in recent years.Read MoreAddressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions
July 2025 | Volume 24 | Issue 7 | Original Article | 659 | Copyright © July 2025
Female hair loss affects over 50% of postmenopausal women, with up to 40% of healthy women experiencing frontal/parietal hair loss, often beginning around reproductive age. Androgenetic alopecia ...
Read MoreOral Minoxidil Media Coverage: The Impact on Patient Perceptions and Practitioner Approaches to Androgenetic Alopecia
January 2024 | Volume 23 | Issue 1 | Editorials | 1364 | Copyright © January 2024
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
September 2023 | Volume 22 | Issue 9 | Original Article | 905 | Copyright © September 2023
Androgenetic alopecia (AGA) is the most common cause of hair loss in men and has limited treatment options. Minoxidil is a common therapeutic option for AGA patients because of its availability. Plate...
Read MoreReal-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
June 2023 | Volume 22 | Issue 6 | Original Article | 559 | Copyright © June 2023
Pattern-type hair loss is a highly prevalent condition affecting the majority of men and women at some point in their lifetime. Although genetics and androgens are instrumental in the pathogenesi...
Read MoreEvaluating the Efficacy of Platelet Rich Plasma and 1550 nm Fractional Laser in Combination and Alone for the Management of Androgenetic Alopecia
November 2022 | Volume 21 | Issue 11 | Original Article | 1166 | Copyright © November 2022
Androgenetic alopecia (AGA) in men and women is the most common cause of hair loss. Affected individuals may experience psychological distress and social withdrawal. Current treatment options for AGA,...
Read MorePlatelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study
September 2022 | Volume 21 | Issue 9 | Original Article | 943 | Copyright © September 2022
Introduction: Platelet-rich plasma (PRP) is a commonly used therapeutic option for androgenetic alopecia (AGA). Evidence syntheses for the impact of PRP on AGA has been handicapped by...
Read MoreMesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice
July 2022 | Volume 21 | Issue 7 | Original Article | 742 | Copyright © July 2022
Background: 5-alpha inhibitors are an effective treatment for androgenetic alopecia. Mesotherapy with dutasteride has been proposed as an effective method to improve hair loss and reducing systemic ab...
Read MoreRetrospective Study of Covid Related Hair Loss
July 2022 | Volume 21 | Issue 7 | Original Article | 724 | Copyright © July 2022
The Novel Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus two and primarily affects the epithelium of the airways. Multiple cutaneous manifestations of COVID-...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
